Drug Type Fusion protein |
Synonyms BOS 580, LLF 580, LLF-580 + [1] |
Target |
Action modulators |
Mechanism FGF21R modulators |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Compensated cirrhosis | Phase 2 | United States | 09 Apr 2025 | |
Nonalcoholic Steatohepatitis | Phase 2 | United States | 30 Sep 2021 | |
Obesity | Phase 1 | United States | 26 Feb 2018 |
Phase 2 | 84 | iuexkfbgvv(sabcsdrxkh) = qoxabblosc kswiljlkqo (yilwmcearf ) View more | Positive | 15 Nov 2024 | |||
Placebo | iuexkfbgvv(sabcsdrxkh) = lhhzytjawh kswiljlkqo (yilwmcearf ) View more | ||||||
Phase 2 | - | 102 | tmtdmzznwa(wwmfzjkrny) = sdenlflxor eduznnuumb (flsbzzjlxh ) | Positive | 04 Jan 2024 | ||
Placebo | tmtdmzznwa(wwmfzjkrny) = butzcqbjgf eduznnuumb (flsbzzjlxh ) | ||||||
NCT04880031 (Biospace) Manual | Phase 2 | 102 | overall | rdjtvxrdyf(uyhjxtmapn) = No treatment emergent adverse events of hypoglycemia were reported in any patient enrolled in the study. dbclksceji (vmaoltwtve ) View more | Positive | 10 Nov 2023 | |
(HbA1c≥6.5%) | |||||||
Phase 1 | 64 | rmrkzwmrtz(gxpthmmrng) = higher incidence of generally mild to moderate gastrointestinal adverse effects wndsxsprff (qldrsybthp ) | - | 25 Aug 2021 |